Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022303 · ClinicalTrials.gov registry record · Phase 2
AT1001 for the Treatment of COVID-19 Related MIS-C
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT05022303: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT05022303 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05022303, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary aim of this study is to evaluate the efficacy and safety of AT1001 versus placebo in pediatric patients with SARS-CoV-2 infection who experience early signs of MIS-C and are at high risk of progression. AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) or matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
Interventions
- DRUG Placebo
- DRUG Larazotide Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2024-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05022303
The ClinicalTrials.gov registry entry for NCT05022303 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05022303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05022303 about?
NCT05022303 is a clinical study titled "AT1001 for the Treatment of COVID-19 Related MIS-C". The primary aim of this study is to evaluate the efficacy and safety of AT1001 versus placebo in pediatric patients with SARS-CoV-2 infection who experience early signs of MIS-C and are at high risk of progression. AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) or matching pl...
What is the current status of trial NCT05022303?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-10-01. Estimated completion is 2024-05-15.
What interventions are being tested in trial NCT05022303?
The interventions under investigation include: Placebo (DRUG), Larazotide Acetate (DRUG).
Who is sponsoring clinical trial NCT05022303?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.